A Study of Rituximab (MabThera) Subcutaneous (SC) Versus Rituximab (MabThera) Intravenous in Participannts With Follicular Non-Hodgkin's Lymphoma
NCT01200758
Completed
This two-stage, multi-center, randomized, controlled, open-label study will investigate the pharmacokinetics, efficacy and safety of rituximab SC versus rituximab IV in participants with previously untreated follicular non-Hodgkin's lymphoma. Participants will be randomized to receive 375 milligrams per meter square (mg/m\^2) rituximab as IV infusion or 1400 milligrams (mg) rituximab SC. In addition, participants will receive standard chemotherapy. Participants who achieved a complete or partial... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/29/2018
Locations: Gosford Hospital; Cancer Care Services, Gosford, New South Wales +151 locations
Conditions: Non-Hodgkin's Lymphoma
Register for Updates
Combination Chemotherapy in Treating Patients With Early Stage Breast Cancer That Has Been Removed By Surgery
NCT00301925
Unknown
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. Giving combination chemotherapy after surgery may kill any remaining tumor cells. It is not yet known which combination chemotherapy regimen is more effective in treating early stage breast cancer that has been removed by surgery. PURPOSE: This randomized phas... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
08/07/2018
Locations: William Harvey Hospital, Ashford-Kent, England +151 locations
Conditions: Breast Cancer
Register for Updates
NY-ESO-1 T Cells in OG Cancer
NCT01795976
Terminated
This is a trial of adoptive T cell therapy using the patient's own T cells, genetically engineered to target the tumour associated antigen NY-ESO-1 (New York esophageal squamous cell carcinoma 1). Eligible patients will undergo leukapheresis (a process to remove white blood cells) to retrieve sufficient T cells which will be gene modified and expanded in the laboratory. Patients will undergo preconditioning chemotherapy with cyclophosphamide (60mg/kg) day -7 and day -6, followed by fludarabine (... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/06/2018
Locations: The Christie NHS Foundation Trust, Manchester, Not set
Conditions: Oesophageal Cancer
Register for Updates
Use of Thalidomide, Lenalidomide, Carfilzomib, Bortezomib and Vorinostat in the Initial Treatment of Newly Diagnosed Multiple Myeloma Patients
NCT01554852
Unknown
The purpose of this study is to compare a standard chemotherapy regimen of cyclophosphamide, dexamethasone plus thalidomide with a newer regimen of cyclophosphamide, dexamethasone plus lenalidomide with or without carfilzomib. Patients who do not have the best response to their initial treatment may then also be given a combination of cyclophosphamide, dexamethasone plus bortezomib. Patients who are relatively fit may, on their doctor's advice, go on to receive more intensive chemotherapy, sup... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/07/2018
Locations: 112 sites UK wide, United Kingdom, Not set
Conditions: Multiple Myeloma
Register for Updates
CHOP vs GEM-P in 1st Line Treatment of T-cell Lymphoma, Multicentre Phase II Study
NCT01719835
Unknown
This is a randomised, open-label phase II study comparing GEM-P chemotherapy (experimental arm) with CHOP (control arm) in previously untreated T-cell lymphoma. Eligible patients will be randomised 1:1 between 4-weekly GEM-P or 3-weekly CHOP chemotherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/13/2018
Locations: Royal Marsden NHS Foundation Trust - London and Surrey, London, Not set
Conditions: Peripheral T-cell Lymphoma NOS, Anaplastic Large Cell Lymphoma, ALK-Negative, Angioimmunoblastic T-cell Lymphoma, Hepatosplenic Gamma/ Delta T-cell Lymphoma, Enteropathy-Associated T-Cell Lymphoma
Register for Updates
IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma
NCT01265901
Completed
The primary objective of the phase III study is to investigate whether IMA901 can prolong overall survival in patients with metastatic and/or locally advanced renal cell carcinoma (RCC) when added to standard first-line therapy with sunitinib. Secondary objectives include a subgroup analysis of overall survival in patients defined by a certain biomarker signature, the investigation of progression-free survival, best tumor response, safety, and immunological parameters.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/04/2017
Locations: University of Arkansas for Medical Sciences, Little Rock, Arkansas +105 locations
Conditions: Metastatic Renal Cell Carcinoma
Register for Updates
Pembrolizumab Cyclophosphamide and Lenalidomide for Patients With Relapsed Multiple Myeloma
NCT03191981
Withdrawn
This is a multi-centre phase I/II trial with an initial dose finding phase for cyclophosphamide and lenalidomide combined with fixed dose pembrolizumab for patients with relapsed or relapsed / refractory multiple myeloma (MM) that have had at least 1 prior line of therapy
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
08/22/2017
Locations: Queen Elizabeth Hospital, Birmingham, Not set +3 locations
Conditions: Myeloma Multiple
Register for Updates
FCR Versus FC Alone in the Treatment of Chronic Lymphocytic Leukemia (CLL) in Relapsed Patients
NCT00090051
Completed
The purpose of this study is to provide treatment for patients who have chronic lymphocytic leukemia (CLL), and to compare the use of rituximab added to fludarabine+cyclophosphamide (FC) with FC alone, to determine if rituximab lengthens the time a patient remains free of leukemia symptoms.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/05/2017
Locations: Uab Comprehensive Cancer Center, Birmingham, Alabama +105 locations
Conditions: Chronic Lymphocytic Leukemia
Register for Updates
A Phase 1 Study of Brentuximab Vedotin Given Sequentially and Combined With Multi-Agent Chemotherapy for CD30-Positive Mature T-Cell and NK-Cell Neoplasms
NCT01309789
Completed
The purpose of this study is to assess the safety profile of brentuximab vedotin sequentially and in combination with multi-agent chemotherapy in front-line treatment for CD30-positive mature T-cell and NK-cell neoplasms, including systemic anaplastic large cell lymphoma. It is a phase 1, open-label, dose escalation study in three arms designed to define the MTD, PK, immunogenicity, and anti-tumor activity of brentuximab vedotin in sequence and in combination with multi-agent front-line chemothe... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/27/2017
Locations: UAB Comprehensive Cancer Center, Birmingham, Alabama +10 locations
Conditions: Lymphoma, Large-Cell, Anaplastic, Lymphoma, NK-cell, Lymphoma, T-cell
Register for Updates
Intergroup Randomized Trial for Children or Adolescents With B-Cell Non Hodgkin Lymphoma or B-Acute Leukemia: Rituximab Evaluation in High Risk Patients
NCT01516580
Unknown
The aim of the trial is to test whether adding 6 injections of rituximab to standard "Lymphome malin B" LMB chemotherapy regimen improves the Event Free Survival (EFS) compared with LMB chemotherapy alone in children / adolescents with advanced stage B-cell Non-Hodgkin Lymphoma (NHL) / B-Acute Leukemia (B-AL)(stage III and LDH \> Nx2, any stage IV or B-AL).
Gender:
ALL
Ages:
Between 6 months and 17 years
Trial Updated:
06/13/2017
Locations: University Hospitals Leuven, Leuven, Not set +9 locations
Conditions: B-cell Non Hodgkin Lymphoma, Mature B-cell Leukemia Burkitt-type
Register for Updates
A Phase II Study VEPEMB In Patients With Hodgkin's Lymphoma Aged ≥ 60 Years
NCT00079105
Completed
RATIONALE: Drugs used in chemotherapy, such as vinblastine, cyclophosphamide, procarbazine, prednisolone, etoposide, mitoxantrone, and bleomycin, work in different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one chemotherapy drug may kill more cancer cells. PURPOSE: This phase II trial is studying how well combination chemotherapy works in treating older patients with previously untreated Hodgkin's lymphoma.
Gender:
ALL
Ages:
Between 60 years and 120 years
Trial Updated:
03/29/2017
Locations: Medizinische Universitaetsklinik I at the University of Cologne, Cologne, Not set +53 locations
Conditions: Lymphoma
Register for Updates
A Study of Obinutuzumab in Combination With Chemotherapy in Participants With CD20+ B-Cell Follicular Non-Hodgkin's Lymphoma
NCT00825149
Completed
This open-label, randomized, phase Ib study will assess the safety and efficacy of obinutuzumab given in combination with FC (fludarabine and cyclophosphamide) or CHOP (cyclophosphamide, doxorubicin, vincristine and prednisolone) or bendamustine induction chemotherapy in participants with Cluster of Differentiation (CD) 20+ B-cell Follicular Lymphoma (FL). Participants with complete response or partial response after induction therapy may receive maintenance therapy every 3 months for 2 years or... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/03/2016
Locations: Not set, Kogarah, New South Wales +33 locations
Conditions: Non-Hodgkin's Lymphoma
Register for Updates